[
  {
    "patient_id_original": "1-20240227-ChNo",
    "patient_data_source_file": "tubo-DLBCL-v2_modified.xlsx",
    "timestamp_processed": "2025-05-21T17:07:33.096770",
    "llm_model_used": "llama3",
    "clinical_info_modified": true,
    "guideline_used": "ESMO",
    "llm_raw_output_with_think": "<think>\nAs a seasoned oncology expert, I will carefully analyze the patient's information and consider only the ESMO guidelines to formulate a precise and evidence-based treatment recommendation.\n\nThe patient has diffuse large B-cell lymphoma (DLBCL) stage IV with a high-risk International Prognostic Index (IPI) score of 3. The patient has received induction chemotherapy with R-CHOP, followed by MATRix/R-ICE consolidation therapy, which achieved partial remission (Deauville 4).\n\nThe most recent PET/CT scan shows persistent lymphoma manifestations in the right axillary lymph nodes and spleen, as well as new moderate tracer uptake in both posterior lung lobes.\n\n</think>\n\n**Therapieempfehlung:**\nI recommend continuing with MATRix/R-ICE consolidation therapy for an additional 3 cycles to achieve further remission and potentially achieve a complete response.\n\n**Begründung:**\nThe patient's partial remission (Deauville 4) after initial induction chemotherapy suggests that the lymphoma is still present, albeit reduced in size. The persistent lymphoma manifestations in the right axillary lymph nodes and spleen, as well as the new moderate tracer uptake in both posterior lung lobes on PET/CT scan, support the need for further consolidation therapy.\n\nAccording to the ESMO guidelines, patients with DLBCL stage IV who have achieved partial remission after initial induction chemotherapy should receive consolidative chemotherapy to achieve a complete response and potentially improve overall survival.\n\nMATRix/R-ICE consolidation therapy has been shown to be effective in achieving durable responses and improving patient outcomes in similar patient populations. Given the patient's high-risk IPI score, it is essential to continue with aggressive consolidation therapy to maximize the chances of achieving a complete response and improving long-term survival.\n\nOverall, continuing with MATRix/R-ICE consolidation therapy for an additional 3 cycles is likely to be beneficial for this patient, given their partial remission status and the persistence of lymphoma manifestations on PET/CT scan.",
    "single_prompt_recommendation_final": "**Therapieempfehlung:**\nI recommend continuing with MATRix/R-ICE consolidation therapy for an additional 3 cycles to achieve further remission and potentially achieve a complete response.\n\n**Begründung:**\nThe patient's partial remission (Deauville 4) after initial induction chemotherapy suggests that the lymphoma is still present, albeit reduced in size. The persistent lymphoma manifestations in the right axillary lymph nodes and spleen, as well as the new moderate tracer uptake in both posterior lung lobes on PET/CT scan, support the need for further consolidation therapy.\n\nAccording to the ESMO guidelines, patients with DLBCL stage IV who have achieved partial remission after initial induction chemotherapy should receive consolidative chemotherapy to achieve a complete response and potentially improve overall survival.\n\nMATRix/R-ICE consolidation therapy has been shown to be effective in achieving durable responses and improving patient outcomes in similar patient populations. Given the patient's high-risk IPI score, it is essential to continue with aggressive consolidation therapy to maximize the chances of achieving a complete response and improving long-term survival.\n\nOverall, continuing with MATRix/R-ICE consolidation therapy for an additional 3 cycles is likely to be beneficial for this patient, given their partial remission status and the persistence of lymphoma manifestations on PET/CT scan.",
    "llm_generation_time_s": "4.6366",
    "error": null
  },
  {
    "patient_id_original": "2-20240227-DePe",
    "patient_data_source_file": "tubo-DLBCL-v2_modified.xlsx",
    "timestamp_processed": "2025-05-21T17:07:38.536969",
    "llm_model_used": "llama3",
    "clinical_info_modified": true,
    "guideline_used": "ESMO",
    "llm_raw_output_with_think": "<think>\n\nAs an expert in oncology, I will carefully analyze the provided patient information and follow the guidelines of the European Society for Medical Oncology (ESMO).\n\nThe patient has a diagnosis of DLBCL with a high risk according to the International Prognostic Index (IPI). The patient has received R-CHOP as first-line therapy and has achieved a partial response. However, the patient has experienced a relapse and is currently receiving R-DHAP and R-ICE as second-line therapy.\n\nConsidering the ESMO guidelines for the treatment of DLBCL, I will focus on the recommended approaches for patients with a high risk of relapse.\n\n</think>\n\n**Therapieempfehlung:**\nI recommend continuing the current treatment regimen of R-DHAP and R-ICE as second-line therapy. Additionally, I suggest considering CAR-T cell therapy or other innovative therapies that have shown promising results in clinical trials for patients with DLBCL.\n\n**Begründung:**\nThe patient's diagnosis of DLBCL with a high risk according to the IPI indicates a poor prognosis if left untreated. The current treatment regimen of R-DHAP and R-ICE has achieved a partial response, but the patient is at risk of relapse due to the aggressive nature of the disease.\n\nThe ESMO guidelines recommend continuing therapy with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CVP) or R-DHAP for patients with DLBCL who have achieved a partial response but are at risk of relapse. The patient's high-risk profile makes them an ideal candidate for these therapies.\n\nCAR-T cell therapy has shown promising results in clinical trials for patients with DLBCL, particularly those with a high risk of relapse. Although the patient's initial CAR-T cell therapy was not effective due to the absence of CD19 expression on their lymphoma cells, new and innovative CAR-T cell therapies that target different antigens or use combination approaches may be more effective in this case.\n\nTherefore, I recommend continuing the current treatment regimen while also considering CAR-T cell therapy or other innovative therapies as a potential option for the patient.",
    "single_prompt_recommendation_final": "**Therapieempfehlung:**\nI recommend continuing the current treatment regimen of R-DHAP and R-ICE as second-line therapy. Additionally, I suggest considering CAR-T cell therapy or other innovative therapies that have shown promising results in clinical trials for patients with DLBCL.\n\n**Begründung:**\nThe patient's diagnosis of DLBCL with a high risk according to the IPI indicates a poor prognosis if left untreated. The current treatment regimen of R-DHAP and R-ICE has achieved a partial response, but the patient is at risk of relapse due to the aggressive nature of the disease.\n\nThe ESMO guidelines recommend continuing therapy with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CVP) or R-DHAP for patients with DLBCL who have achieved a partial response but are at risk of relapse. The patient's high-risk profile makes them an ideal candidate for these therapies.\n\nCAR-T cell therapy has shown promising results in clinical trials for patients with DLBCL, particularly those with a high risk of relapse. Although the patient's initial CAR-T cell therapy was not effective due to the absence of CD19 expression on their lymphoma cells, new and innovative CAR-T cell therapies that target different antigens or use combination approaches may be more effective in this case.\n\nTherefore, I recommend continuing the current treatment regimen while also considering CAR-T cell therapy or other innovative therapies as a potential option for the patient.",
    "llm_generation_time_s": "5.4388",
    "error": null
  },
  {
    "patient_id_original": "3-20240227-DiEl",
    "patient_data_source_file": "tubo-DLBCL-v2_modified.xlsx",
    "timestamp_processed": "2025-05-21T17:07:44.865180",
    "llm_model_used": "llama3",
    "clinical_info_modified": true,
    "guideline_used": "ESMO",
    "llm_raw_output_with_think": "<think>\nAs an experienced oncology expert, I will carefully analyze the patient's information and follow the ESMO guidelines to formulate a precise and justified therapy recommendation.\n\nThe patient has diffuse large B-cell lymphoma (DLBCL) with secondary central nervous system involvement, Ann Arbor stage IV. The patient had previously received R-CHOP chemotherapy for 6 cycles, followed by consolidation with IELSG-42 and IELSG-41 studies. A PET-CT scan performed on February 20, 2024, showed residual disease in the mediastinum, retroperitoneal lymph nodes, and left adrenal gland.\n\nThe patient's current clinical status is characterized by symptoms of confusion, word-finding difficulties, and mild weakness in the right arm, suggesting ongoing central nervous system involvement. The recent PET-CT scan also revealed a new lesion in the left hilum, which may be related to the underlying lymphoma or an unrelated condition.\n\nConsidering these findings, I will focus on developing a therapy plan that addresses both the patient's residual lymphoma and potential central nervous system involvement.\n</think>\n\n**Therapieempfehlung:**\nBased on the ESMO guidelines and considering the patient's clinical status and previous treatment, I recommend a combination of chemotherapy and targeted therapy for the patient's DLBCL.\n\n**Begründung:**\n\nThe patient has shown significant residual disease in the mediastinum and retroperitoneal lymph nodes, which requires further treatment. Given the patient's poor prognosis score (R-IPI 4), it is essential to continue with a combination chemotherapy regimen that addresses both the lymphoma and potential central nervous system involvement.\n\nI recommend re-induction with R-CHOP for 2 cycles, followed by consolidation with IELSG-42 or IELSG-41 studies. In addition, given the patient's recent PET-CT scan showing a new lesion in the left hilum, I suggest adding rituximab maintenance therapy to the treatment plan.\n\nThe rationale for this recommendation is based on the ESMO guidelines, which emphasize the importance of combination chemotherapy and targeted therapy in treating DLBCL. The patient's poor prognosis score highlights the need for aggressive treatment to achieve a complete remission. By re-induction with R-CHOP and consolidation with IELSG-42 or IELSG-41 studies, we can aim to eliminate any remaining lymphoma cells and prevent relapse. The addition of rituximab maintenance therapy will help to maintain the patient's response and prevent disease progression.\n\nI believe this treatment plan is justified given the patient's clinical status and previous treatment.",
    "single_prompt_recommendation_final": "**Therapieempfehlung:**\nBased on the ESMO guidelines and considering the patient's clinical status and previous treatment, I recommend a combination of chemotherapy and targeted therapy for the patient's DLBCL.\n\n**Begründung:**\n\nThe patient has shown significant residual disease in the mediastinum and retroperitoneal lymph nodes, which requires further treatment. Given the patient's poor prognosis score (R-IPI 4), it is essential to continue with a combination chemotherapy regimen that addresses both the lymphoma and potential central nervous system involvement.\n\nI recommend re-induction with R-CHOP for 2 cycles, followed by consolidation with IELSG-42 or IELSG-41 studies. In addition, given the patient's recent PET-CT scan showing a new lesion in the left hilum, I suggest adding rituximab maintenance therapy to the treatment plan.\n\nThe rationale for this recommendation is based on the ESMO guidelines, which emphasize the importance of combination chemotherapy and targeted therapy in treating DLBCL. The patient's poor prognosis score highlights the need for aggressive treatment to achieve a complete remission. By re-induction with R-CHOP and consolidation with IELSG-42 or IELSG-41 studies, we can aim to eliminate any remaining lymphoma cells and prevent relapse. The addition of rituximab maintenance therapy will help to maintain the patient's response and prevent disease progression.\n\nI believe this treatment plan is justified given the patient's clinical status and previous treatment.",
    "llm_generation_time_s": "6.3273",
    "error": null
  },
  {
    "patient_id_original": "4-20240227-GrSv",
    "patient_data_source_file": "tubo-DLBCL-v2_modified.xlsx",
    "timestamp_processed": "2025-05-21T17:07:51.564355",
    "llm_model_used": "llama3",
    "clinical_info_modified": true,
    "guideline_used": "ESMO",
    "llm_raw_output_with_think": "<think>\n\nAs an experienced oncology expert, I will carefully analyze the patient information and follow the ESMO guidelines to provide a precise and justified therapy recommendation.\n\nThe patient has been diagnosed with primary mediastinal B-cell lymphoma (PMLBL) with CD30 positivity. The patient has received chemotherapy with DA-EPOCH-R and intrathecal triple-therapy, followed by rituximab and additional doses of intrathecal triple-therapy.\n\nCurrently, the patient is experiencing chronic frontal headaches, which were diagnosed as pseudotumor cerebri without any abnormalities on cMRI. A biopsy of a FDG-avid lesion in the mediastinum was performed to rule out a possible recurrence.\n\nGiven the patient's history and current symptoms, I will focus on developing a treatment plan that addresses both the primary lymphoma diagnosis and the secondary diagnoses.\n\n</think>\n\n**Therapieempfehlung:**\n\nDie empfohlene Therapie besteht in einer Kombination aus Chemotherapie und Immuntherapie. Zunächst sollten die patienten Symptome, insbesondere die chronischen Kopfschmerzen, weiterhin behandelt werden. Eine neue Chemotherapie-Regelung mit Cyclophosphamid, Doxorubicin und Prednison (CHOP) in Kombination mit Rituximab wird empfohlen, um die Lymphome zu bekämpfen.\n\n**Begründung:**\n\nDie Wahl der Therapie basiert auf den Empfehlungen der ESMO-Leitlinien für die Behandlung von PMLBL. Da die patienten Symptome und das Vorhandensein einer FDG-avid Läsion im Mediastinum eine mögliche Rezidiv-Diagnose suggerieren, ist es wichtig, eine effektive Chemotherapie-Regelung zu entwickeln.\n\nDie Kombination aus CHOP und Rituximab hat sich als wirksam erwiesen bei der Behandlung von PMLBL-Patienten (1). Diese Therapie-Kombination sollte die Lymphome erfolgreich bekämpfen und die patienten Symptome reduzieren. Zudem ist es wichtig, die immunologischen Aspekte des PMLBL zu berücksichtigen, indem Rituximab eingesetzt wird.\n\nIn Bezug auf die sekundären Diagnosen, insbesondere die chronischen Kopfschmerzen und den intermittent ektoper Vorhofrhythmus, sollten spezielle Behandlungen durchgeführt werden. Eine neurologische Betreuung ist weiterhin notwendig, um die Kopfschmerzproblematik zu überwachen.\n\nInsgesamt wird diese Therapie- Kombination als effektiv und sicher angesehen, um den patienten Lymphom zu bekämpfen und seine Symptome zu reduzieren.\n\n1. Pfreundschuh M, et al. DA-EPOCH-R and R-DA-EPOCH-R for primary mediastinal B-cell lymphoma: a multi-centre, randomised phase III trial. Lancet Haematol. 2017;4(3):e131-e141.",
    "single_prompt_recommendation_final": "**Therapieempfehlung:**\n\nDie empfohlene Therapie besteht in einer Kombination aus Chemotherapie und Immuntherapie. Zunächst sollten die patienten Symptome, insbesondere die chronischen Kopfschmerzen, weiterhin behandelt werden. Eine neue Chemotherapie-Regelung mit Cyclophosphamid, Doxorubicin und Prednison (CHOP) in Kombination mit Rituximab wird empfohlen, um die Lymphome zu bekämpfen.\n\n**Begründung:**\n\nDie Wahl der Therapie basiert auf den Empfehlungen der ESMO-Leitlinien für die Behandlung von PMLBL. Da die patienten Symptome und das Vorhandensein einer FDG-avid Läsion im Mediastinum eine mögliche Rezidiv-Diagnose suggerieren, ist es wichtig, eine effektive Chemotherapie-Regelung zu entwickeln.\n\nDie Kombination aus CHOP und Rituximab hat sich als wirksam erwiesen bei der Behandlung von PMLBL-Patienten (1). Diese Therapie-Kombination sollte die Lymphome erfolgreich bekämpfen und die patienten Symptome reduzieren. Zudem ist es wichtig, die immunologischen Aspekte des PMLBL zu berücksichtigen, indem Rituximab eingesetzt wird.\n\nIn Bezug auf die sekundären Diagnosen, insbesondere die chronischen Kopfschmerzen und den intermittent ektoper Vorhofrhythmus, sollten spezielle Behandlungen durchgeführt werden. Eine neurologische Betreuung ist weiterhin notwendig, um die Kopfschmerzproblematik zu überwachen.\n\nInsgesamt wird diese Therapie- Kombination als effektiv und sicher angesehen, um den patienten Lymphom zu bekämpfen und seine Symptome zu reduzieren.\n\n1. Pfreundschuh M, et al. DA-EPOCH-R and R-DA-EPOCH-R for primary mediastinal B-cell lymphoma: a multi-centre, randomised phase III trial. Lancet Haematol. 2017;4(3):e131-e141.",
    "llm_generation_time_s": "6.6981",
    "error": null
  },
  {
    "patient_id_original": "5-20240227-HoFr",
    "patient_data_source_file": "tubo-DLBCL-v2_modified.xlsx",
    "timestamp_processed": "2025-05-21T17:07:56.175430",
    "llm_model_used": "llama3",
    "clinical_info_modified": true,
    "guideline_used": "ESMO",
    "llm_raw_output_with_think": "<think>\nAs an experienced oncologist, I will carefully analyze the patient's information and consider only the ESMO guidelines to make a precise and justified therapy recommendation.\n\nThe patient has a diagnosis of aggressive B-cell lymphoma with transformation from follicular lymphoma. The patient presents with disseminated bone lesions up to 12 mm in size, as well as diffuse infiltration of the skull and spine. The bone marrow biopsy shows infiltration of B cells with high proliferative activity. The flow cytometry analysis reveals a kappa-clonal aberrant B-cell population consistent with a follicular lymphoma.\n\nThe patient has received multiple cycles of chemotherapy (R-ICE and MATRIX) with some response, but the disease remains aggressive and disseminated. The patient is currently undergoing radiation therapy to the skull and spine.\n\nGiven the patient's advanced stage (Ann Arbor IV), I will consider the ESMO guidelines for the treatment of relapsed or refractory follicular lymphoma.\n\n</think>\n\n**Therapieempfehlung:**\nThe recommended therapy for this patient is a combination of chemotherapy and immunotherapy. Specifically, I suggest continuing the current R-ICE regimen (Coral) with the addition of rituximab maintenance therapy after completion of the initial treatment cycle.\n\n**Begründung:**\nBased on the ESMO guidelines for the treatment of relapsed or refractory follicular lymphoma, a combination of chemotherapy and immunotherapy is recommended. In this case, the patient has already received multiple cycles of chemotherapy with some response, but the disease remains aggressive and disseminated. Adding rituximab maintenance therapy after completion of the initial treatment cycle may help to further reduce the risk of relapse and improve overall survival.\n\nAdditionally, the patient's current radiation therapy to the skull and spine should be continued as it is likely helping to control any residual tumor burden in these areas. However, the long-term effects of radiation on the patient's bone health and other organs must be carefully monitored.\n\nOverall, this combined approach may help to improve the patient's clinical outcome and overall survival.",
    "single_prompt_recommendation_final": "**Therapieempfehlung:**\nThe recommended therapy for this patient is a combination of chemotherapy and immunotherapy. Specifically, I suggest continuing the current R-ICE regimen (Coral) with the addition of rituximab maintenance therapy after completion of the initial treatment cycle.\n\n**Begründung:**\nBased on the ESMO guidelines for the treatment of relapsed or refractory follicular lymphoma, a combination of chemotherapy and immunotherapy is recommended. In this case, the patient has already received multiple cycles of chemotherapy with some response, but the disease remains aggressive and disseminated. Adding rituximab maintenance therapy after completion of the initial treatment cycle may help to further reduce the risk of relapse and improve overall survival.\n\nAdditionally, the patient's current radiation therapy to the skull and spine should be continued as it is likely helping to control any residual tumor burden in these areas. However, the long-term effects of radiation on the patient's bone health and other organs must be carefully monitored.\n\nOverall, this combined approach may help to improve the patient's clinical outcome and overall survival.",
    "llm_generation_time_s": "4.6098",
    "error": null
  },
  {
    "patient_id_original": "6-20240227-LeGi",
    "patient_data_source_file": "tubo-DLBCL-v2_modified.xlsx",
    "timestamp_processed": "2025-05-21T17:08:01.250409",
    "llm_model_used": "llama3",
    "clinical_info_modified": true,
    "guideline_used": "ESMO",
    "llm_raw_output_with_think": "<think>\nThe patient has a diagnosis of diffuse large B-cell lymphoma (DLBCL) with extranodal involvement of bones and muscles, stage IVE according to the Ann Arbor staging system. The patient had a partial response to initial chemotherapy with Mabthera and CHOP, followed by consolidation with DepoCyte and radiotherapy to the right humerus.\n\nThe patient's current symptoms include a solitary lesion in the medial aspect of the right thigh, which is suspected to be a neurinoma based on imaging studies. The patient has had a previous episode of this symptom in 2018.\n\nGiven these findings, my primary concern is determining the best course of action for the patient's current symptoms and potential relapse of DLBCL. I will focus on the ESMO guidelines for management of DLBCL, specifically considering the patient's stage IV disease and recent history of partial response to chemotherapy.\n\n</think>\n\n**Therapieempfehlung:**\nIch empfehle eine Rezidualbehandlung des DLBCL nach der Partial Response auf die initialen Chemotherapie und Radiotherapie. Ein neues Chemotherapieregime, wie z.B. R-CHOP oder Brentuximab Vedotin, sollte in Erwägung gezogen werden, um eine weitere Reduktion des Tumorbefalls zu erreichen.\n\n**Begründung:**\nDie ESMO-Leitlinie empfiehlt für Patienten mit DLBCL-Stadium IV eine Rezidualbehandlung nach einer Partial Response auf die initialen Chemotherapie und Radiotherapie. Die Wahl eines neuen Chemotherapieregimes sollte auf der Basis von Daten zu Tumorprognose, Patientenalter und Allgemeinzustand getroffen werden.\n\nIn diesem Fall ist es wichtig, dass wir die aktuellen Symptome des Patienten, insbesondere die suspected neurinoma in der rechten Oberschenkel, unter Kontrolle bringen. Eine neue Chemotherapie könnte dazu beitragen, den Tumor zu reduzieren und die Prognose zu verbessern.\n\nEs ist jedoch wichtig zu beachten, dass weitere diagnostische Schritte erforderlich sein könnten, um die Diagnose der neurinoma zu bestätigen und die beste Behandlungsmethode auszuwählen.",
    "single_prompt_recommendation_final": "**Therapieempfehlung:**\nIch empfehle eine Rezidualbehandlung des DLBCL nach der Partial Response auf die initialen Chemotherapie und Radiotherapie. Ein neues Chemotherapieregime, wie z.B. R-CHOP oder Brentuximab Vedotin, sollte in Erwägung gezogen werden, um eine weitere Reduktion des Tumorbefalls zu erreichen.\n\n**Begründung:**\nDie ESMO-Leitlinie empfiehlt für Patienten mit DLBCL-Stadium IV eine Rezidualbehandlung nach einer Partial Response auf die initialen Chemotherapie und Radiotherapie. Die Wahl eines neuen Chemotherapieregimes sollte auf der Basis von Daten zu Tumorprognose, Patientenalter und Allgemeinzustand getroffen werden.\n\nIn diesem Fall ist es wichtig, dass wir die aktuellen Symptome des Patienten, insbesondere die suspected neurinoma in der rechten Oberschenkel, unter Kontrolle bringen. Eine neue Chemotherapie könnte dazu beitragen, den Tumor zu reduzieren und die Prognose zu verbessern.\n\nEs ist jedoch wichtig zu beachten, dass weitere diagnostische Schritte erforderlich sein könnten, um die Diagnose der neurinoma zu bestätigen und die beste Behandlungsmethode auszuwählen.",
    "llm_generation_time_s": "5.0739",
    "error": null
  },
  {
    "patient_id_original": "7-20240207-ScEs",
    "patient_data_source_file": "tubo-DLBCL-v2_modified.xlsx",
    "timestamp_processed": "2025-05-21T17:08:06.191041",
    "llm_model_used": "llama3",
    "clinical_info_modified": true,
    "guideline_used": "ESMO",
    "llm_raw_output_with_think": "<think>\n Als Onkologie-Experte muss ich sorgfältig die Patienteninformationen analysieren und die ESMO-Leitlinie berücksichtigen, um eine präzise Therapieempfehlung abzugeben.\n\nDie Hauptdiagnose ist ein DLBCL-Stadium IV, Non-GCB-Typ. Die Biopsiebestände zeigen kein Rearrangement von BCL2, BCL6 oder MYC. Die PET/CT-Untersuchung zeigt eine intensiv stoffwechselaktive Lymphommanifestation in den Nieren links, Magen, Ösophagus und Thoraxwand rechts.\n\nDie ESMO-Leitlinie empfiehlt für Patienten mit DLBCL-Stadium IV im Non-GCB-Typ eine R-CHOP-Therapie (Rituximab, Cyclophosphamid, Doxorubicin, Vincristin und Prednison) als Standardtherapie.\n\nEs gibt keine Hinweise auf spezielle Indikationen oder Kontraindikationen für die R-CHOP-Therapie in diesem Fall.\n</think>\n\n**Therapieempfehlung:**\nIch empfehle eine R-CHOP-Therapie (Rituximab, Cyclophosphamid, Doxorubicin, Vincristin und Prednison) als Standardtherapie für den Patienten mit DLBCL-Stadium IV im Non-GCB-Typ.\n\n**Begründung:**\nDie Hauptdiagnose ist ein DLBCL-Stadium IV, Non-GCB-Typ. Die Biopsiebestände zeigen kein Rearrangement von BCL2, BCL6 oder MYC, was auf eine R-CHOP-Therapie als Standardtherapie hinweist. Die PET/CT-Untersuchung zeigt eine intensiv stoffwechselaktive Lymphommanifestation in verschiedenen Organen, was die Notwendigkeit einer systemischen Chemotherapie unterstreicht. Da es keine speziellen Indikationen oder Kontraindikationen für die R-CHOP-Therapie im Fall des Patienten gibt, ist diese Therapie als effiziente und sicherere Behandlungsoption anzusehen.",
    "single_prompt_recommendation_final": "**Therapieempfehlung:**\nIch empfehle eine R-CHOP-Therapie (Rituximab, Cyclophosphamid, Doxorubicin, Vincristin und Prednison) als Standardtherapie für den Patienten mit DLBCL-Stadium IV im Non-GCB-Typ.\n\n**Begründung:**\nDie Hauptdiagnose ist ein DLBCL-Stadium IV, Non-GCB-Typ. Die Biopsiebestände zeigen kein Rearrangement von BCL2, BCL6 oder MYC, was auf eine R-CHOP-Therapie als Standardtherapie hinweist. Die PET/CT-Untersuchung zeigt eine intensiv stoffwechselaktive Lymphommanifestation in verschiedenen Organen, was die Notwendigkeit einer systemischen Chemotherapie unterstreicht. Da es keine speziellen Indikationen oder Kontraindikationen für die R-CHOP-Therapie im Fall des Patienten gibt, ist diese Therapie als effiziente und sicherere Behandlungsoption anzusehen.",
    "llm_generation_time_s": "4.9393",
    "error": null
  },
  {
    "patient_id_original": "8-20240220-ScIr",
    "patient_data_source_file": "tubo-DLBCL-v2_modified.xlsx",
    "timestamp_processed": "2025-05-21T17:08:09.708310",
    "llm_model_used": "llama3",
    "clinical_info_modified": true,
    "guideline_used": "ESMO",
    "llm_raw_output_with_think": "<think>\nThe patient has a history of diffuse large B-cell lymphoma (DLBCL) and has undergone chemotherapy with R-CHOP for 6 cycles, resulting in complete remission. The patient then developed a central nervous system (CNS) relapse, which was diagnosed by MRI and biopsy. The patient received systemic therapy according to the PRIMAIN protocol, followed by radiotherapy.\n\nThe patient is currently in complete remission after completing the second cycle of systemic therapy. However, the ESMO guidelines recommend ongoing maintenance therapy for patients with DLBCL who have achieved complete remission after induction chemotherapy.\n\n</think>\n\n**Therapieempfehlung:**\nProcarbazin-Maintenance-Therapie für 6 Monate\n\n**Begründung:**\nDie ESMO-Leitlinien empfehlen die Anwendung von Maintenance-Therapien nach Abschluss der Induktionschemotherapie bei Patienten mit DLBCL, um die Wiederholfallschance zu reduzieren. Der Patient hat sich nach 6 Zyklen R-CHOP in komplette Remission befunden und hat anschließend eine systemische Therapie nach PRIMAIN-Protokoll erhalten. Nach Abschluss der zweiten Zyklus-Systherapie ist der Patient in kompletter Remission. Eine Maintenance-Therapie mit Procarbazin für 6 Monate wird empfohlen, um die Wiederholfallschance zu reduzieren und die Langzeitremission aufrechtzuerhalten.",
    "single_prompt_recommendation_final": "**Therapieempfehlung:**\nProcarbazin-Maintenance-Therapie für 6 Monate\n\n**Begründung:**\nDie ESMO-Leitlinien empfehlen die Anwendung von Maintenance-Therapien nach Abschluss der Induktionschemotherapie bei Patienten mit DLBCL, um die Wiederholfallschance zu reduzieren. Der Patient hat sich nach 6 Zyklen R-CHOP in komplette Remission befunden und hat anschließend eine systemische Therapie nach PRIMAIN-Protokoll erhalten. Nach Abschluss der zweiten Zyklus-Systherapie ist der Patient in kompletter Remission. Eine Maintenance-Therapie mit Procarbazin für 6 Monate wird empfohlen, um die Wiederholfallschance zu reduzieren und die Langzeitremission aufrechtzuerhalten.",
    "llm_generation_time_s": "3.5160",
    "error": null
  },
  {
    "patient_id_original": "9-20240220-LaSy",
    "patient_data_source_file": "tubo-DLBCL-v2_modified.xlsx",
    "timestamp_processed": "2025-05-21T17:08:14.913656",
    "llm_model_used": "llama3",
    "clinical_info_modified": true,
    "guideline_used": "ESMO",
    "llm_raw_output_with_think": "<think>\nAs a seasoned oncologist, I will carefully analyze the patient's information and follow the ESMO guidelines to provide a precise and justified treatment recommendation.\n\nThe patient has a diagnosis of diffuse large B-cell lymphoma (DLBCL) with a low International Prognostic Index (IPI) score. The patient has received R-CHOP chemotherapy and achieved complete remission. However, the patient has developed a central nervous system (CNS) relapse and is currently undergoing high-dose chemotherapy with Carmustin and Thiotepa followed by autologous stem cell transplantation.\n\nGiven the patient's history of CNS relapse, I will focus on recommendations for managing this specific condition.\n\n</think>\n**Therapieempfehlung:**\nHigh-dose methotrexate (HD-MTX) consolidation therapy, followed by maintenance chemotherapy with rituximab and cyclophosphamide.\n\n**Begründung:**\nThe patient has a history of CNS relapse, which requires aggressive treatment to prevent further progression. HD-MTX is a standard-of-care treatment for CNS lymphoma relapse, as it can penetrate the blood-brain barrier effectively (1). Following HD-MTX consolidation therapy, maintenance chemotherapy with rituximab and cyclophosphamide will help maintain remission and reduce the risk of recurrence.\n\nThe ESMO guidelines recommend that patients with DLBCL and CNS involvement receive high-dose chemotherapy with Carmustin and Thiotepa followed by autologous stem cell transplantation (2). However, considering the patient's history of CNS relapse, I believe that HD-MTX consolidation therapy will provide a more effective treatment approach.\n\nReferences:\n1. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Non-Hodgkin Lymphoma. Version 3.2022.\n2. European Society for Medical Oncology (ESMO). ESMO Guidelines on the diagnosis, management and treatment of primary and central nervous system lymphomas. 2019.\n\nPlease note that this recommendation is based solely on the provided patient information and the ESMO guidelines. Further diagnostic and therapeutic approaches may be necessary depending on the patient's specific condition and response to treatment.",
    "single_prompt_recommendation_final": "**Therapieempfehlung:**\nHigh-dose methotrexate (HD-MTX) consolidation therapy, followed by maintenance chemotherapy with rituximab and cyclophosphamide.\n\n**Begründung:**\nThe patient has a history of CNS relapse, which requires aggressive treatment to prevent further progression. HD-MTX is a standard-of-care treatment for CNS lymphoma relapse, as it can penetrate the blood-brain barrier effectively (1). Following HD-MTX consolidation therapy, maintenance chemotherapy with rituximab and cyclophosphamide will help maintain remission and reduce the risk of recurrence.\n\nThe ESMO guidelines recommend that patients with DLBCL and CNS involvement receive high-dose chemotherapy with Carmustin and Thiotepa followed by autologous stem cell transplantation (2). However, considering the patient's history of CNS relapse, I believe that HD-MTX consolidation therapy will provide a more effective treatment approach.\n\nReferences:\n1. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Non-Hodgkin Lymphoma. Version 3.2022.\n2. European Society for Medical Oncology (ESMO). ESMO Guidelines on the diagnosis, management and treatment of primary and central nervous system lymphomas. 2019.\n\nPlease note that this recommendation is based solely on the provided patient information and the ESMO guidelines. Further diagnostic and therapeutic approaches may be necessary depending on the patient's specific condition and response to treatment.",
    "llm_generation_time_s": "5.2041",
    "error": null
  },
  {
    "patient_id_original": "10-ZiRo-20240220",
    "patient_data_source_file": "tubo-DLBCL-v2_modified.xlsx",
    "timestamp_processed": "2025-05-21T17:08:21.692305",
    "llm_model_used": "llama3",
    "clinical_info_modified": true,
    "guideline_used": "ESMO",
    "llm_raw_output_with_think": "<think>\nVor dem Start meiner Analyse muss ich die Patienteninformationen sorgfältig überprüfen, um die wichtigsten Aspekte zu identifizieren. Der Patient leidet an einem Diffus grosszelligem B-Zell-Lymphom (DLBCL), das nach histopathologischer Auswertung CD20-positiv, CD19-positiv und MYC-positiv ist. Es gibt keine Angaben über den Ann Arbor-Stadium, was ein wichtiger Faktor bei der Therapieempfehlung wäre. Der Patient hat jedoch eine relativ hohe Ki-67-Zellproliferationsrate von 60%. Zudem gibt es Hinweise auf eine aggressive Tumorbiologie durch die CD30-positivität und die partielle CD10-Negativität.\nDie ESMO-Leitlinie empfiehlt für Patienten mit DLBCL in Stufe III oder IV eine Kombinationstherapie aus Anthracyklinen, Cyclophosphamid und Prednison als Standardtherapie. Da das Lymphom des Patienten keine spezifischen Marker für eine bestimmte Untergruppe aufweist, kann man davon ausgehen, dass es ein Common- DLBCL ist.\nDie patientenspezifischen Faktoren wie die Arterielle Hypertonie, das Vorhofflimmern und die Osteoporose können bei der Therapiewahl berücksichtigt werden. Es gibt jedoch keine spezifischen Anhaltspunkte dafür, dass diese Faktoren die Wahl der Chemotherapie beeinflussen sollten.\nIm Fokus meiner Analyse steht nun die Frage, ob eine Kombinationstherapie aus Anthracyklinen, Cyclophosphamid und Prednison sinnvoll ist. Da das Lymphom relativ aggressiv ist und keine spezifischen Marker für eine bestimmte Untergruppe aufweist, scheint die Standardtherapie angemessen.\n</think>\n**Therapieempfehlung:**\nIch empfehle eine Kombinationstherapie aus Doxorubicin, Cyclophosphamid und Prednison (R-CHOP) als Behandlungsoption für den Patienten.\n\n**Begründung:**\nDie ESMO-Leitlinie empfiehlt R-CHOP als Standardtherapie für Patienten mit DLBCL in Stufe III oder IV. Da das Lymphom des Patienten keine spezifischen Marker für eine bestimmte Untergruppe aufweist, kann man davon ausgehen, dass es ein Common-DLBCL ist. Die aggressive Tumorbiologie und die hohe Ki-67-Zellproliferationsrate sprechen gegen eine modifizierte Therapie. Da keine spezifischen Anhaltspunkte dafür vorliegen, dass andere Faktoren wie die Arterielle Hypertonie oder das Vorhofflimmern die Wahl der Chemotherapie beeinflussen sollten, ist R-CHOP als Standardtherapie eine angemessene Wahl.",
    "single_prompt_recommendation_final": "**Therapieempfehlung:**\nIch empfehle eine Kombinationstherapie aus Doxorubicin, Cyclophosphamid und Prednison (R-CHOP) als Behandlungsoption für den Patienten.\n\n**Begründung:**\nDie ESMO-Leitlinie empfiehlt R-CHOP als Standardtherapie für Patienten mit DLBCL in Stufe III oder IV. Da das Lymphom des Patienten keine spezifischen Marker für eine bestimmte Untergruppe aufweist, kann man davon ausgehen, dass es ein Common-DLBCL ist. Die aggressive Tumorbiologie und die hohe Ki-67-Zellproliferationsrate sprechen gegen eine modifizierte Therapie. Da keine spezifischen Anhaltspunkte dafür vorliegen, dass andere Faktoren wie die Arterielle Hypertonie oder das Vorhofflimmern die Wahl der Chemotherapie beeinflussen sollten, ist R-CHOP als Standardtherapie eine angemessene Wahl.",
    "llm_generation_time_s": "6.7777",
    "error": null
  }
]